Insight Molecular DiagnosticIMDX
13F holders, Q3 2024 (September 30)20holders −1
3new positions
4sold out
$2.85avg. 13F price*
At the end of Q3 2024, 20 institutions reported holding Insight Molecular Diagnostic (IMDX) in their 13F filings, down 1 from Q2 2024. 3 opened new positions and 4 sold out. The largest holders were Broadwood Capital Inc. ($14.0M), AWM Investment Company, Inc. ($3.1M) and Pura Vida Investments, LLC ($1.4M).
- Company
- Insight Molecular Diagnostic
- Filed as
- ONCOCYTE CORP (Q3 2024)
- CUSIP
- 68235C206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $3.1M |
| Exits | 4 | $32K |
All 13F filers, Q2 2024 → Q3 2024: 1,128,856 shares bought and 19,050 shares sold, net +1,109,806 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 20 holders
| Broadwood Capital Inc. | 1.08% | No change | 4,929,066 | $14.0M |
| AWM Investment Company, Inc. | 0.38% | New | 1,097,175 | $3.1M |
| Pura Vida Investments, LLC | 2.32% | No change | 495,345 | $1.4M |
| Vanguard Group Inc. | 0.00% | Add +0.4% | 245,388 | $699K |
| Geode Capital Management, LLC | 0.00% | Add +12.2% | 103,980 | $296K |
| BlackRock, Inc. | 0.00% | — | 79,833 | $228K |
| Morgan Stanley | 0.00% | Reduce -8.1% | 72,289 | $206K |
| FNY Investment Advisers, LLC | 0.06% | Add +81.3% | 42,896 | $122K |
| State Street Corp. | 0.00% | No change | 19,554 | $56K |
| Northern Trust Corp. | 0.00% | No change | 17,346 | $49K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -52.9% | 1,446 | $4K |
| Osaic Holdings, Inc. | 0.00% | Reduce -4.2% | 1,080 | $3K |
| UBS Group AG | 0.00% | No change | 835 | $2K |
| Bank of America Corp. | 0.00% | Reduce -1.0% | 412 | $1K |
| Wilmington Savings Fund Society, FSB | 0.00% | New | 250 | $713 |
| JPMorgan Chase & Co. | 0.00% | No change | 154 | $439 |
| Piscataqua Savings Bank | 0.00% | No change | 25 | $71 |
| Coppell Advisory Solutions LLC | 0.00% | No change | 10 | $29 |
| Albion Financial Group | 0.00% | No change | 7 | $20 |
| Danske Bank A/S | 0.00% | New | 1 | $3 |
"% of holder's portfolio" is IMDX's weight in each manager's 13F, not the share of Insight Molecular Diagnostic the manager owns.